Plain-English translation of NCT07425054 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a smarter way to treat advanced anal cancer by personalizing radiation therapy based on how your cancer responds early in treatment. Doctors will measure a cancer marker in your blood to see if the cancer is responding well, and adjust your radiation dose accordingly—giving some people less radiation if their cancer is shrinking, and others more intensive treatment plus the immunotherapy drug if their cancer isn't responding as hoped.
Currently, all patients with advanced anal cancer receive the same radiation dose, but some people don't need that much treatment and suffer unnecessary side effects, while others might benefit from a stronger approach. This trial aims to find the right dose for each person based on their individual cancer's response.
You likely qualify if…
You likely don't qualify if…
You will receive radiation therapy combined with for the first 4 weeks while doctors monitor how your cancer responds by testing your blood for cancer markers. Based on those test results, your treatment plan will be adjusted: if your cancer is responding well, you may receive a lower total dose; if it's responding moderately, you'll continue with the standard dose; if it's responding slowly, you'll receive more intensive radiation and then receive the immunotherapy drug after radiation ends. The total treatment will span several weeks depending on which group you're in.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States